Literature DB >> 11466024

Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents.

C Zona1, I Niespodziany, C Marchetti, H Klitgaard, G Bernardi, D G Margineanu.   

Abstract

This study investigated whether the mechanism of action of levetiracetam (LEV) is related to effects on neuronal voltage-gated Na+ or T-type Ca2+currents. Rat neocortical neurones in culture were subjected to the whole-cell mode of voltage clamping under experimental conditions designed to study voltage-gated Na+ current. Additionally, visually identified pyramidal neurones in the CA1 area of rat hippocampal slices were subjected to the whole-cell mode of voltage clamping under experimental conditions designed to study low-voltage-gated (T-type) Ca2+ current. LEV (10 microM-1 mM) did not modify the Na+ current amplitude and did not change (200 microM) the steady-state activation and inactivation, the time to peak, the fast kinetics of the inactivation and the recovery from the steady-state inactivation of the Na+ current. Likewise, LEV (32-100 microM) did not modify the amplitude and did not change the steady-state activation and inactivation, the time to peak, the fast kinetics of the inactivation and the recovery from the steady-state inactivation of the T-type Ca2+current. In conclusion, neuronal voltage-gated Na+ channels do not appear directly involved in the antiepileptic mechanism of action of LEV, and LEV was devoid of effect on the low-voltage-gated (T-type) Ca2+ current in hippocampal neurones. Copyright 2001 BEA Trading Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466024     DOI: 10.1053/seiz.2000.0504

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  26 in total

1.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

2.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

4.  Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.

Authors:  Jonathan Robitsek; Marcia H Ratner; Tara Stewart; Howard Eichenbaum; David H Farb
Journal:  Hippocampus       Date:  2015-07-14       Impact factor: 3.899

5.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus.

Authors:  Chun-Yao Lee; Chih-Chuan Chen; Horng-Huei Liou
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 6.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs.

Authors:  Tobias Leniger; Jan Thöne; Udo Bonnet; Andreas Hufnagel; Dieter Bingmann; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

8.  In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs.

Authors:  Pierangelo Sardo; Stefania D'Agostino; Valerio Rizzo; Fabio Carletti; Gioacchino Lonobile; Giuseppe Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

9.  Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Authors:  Stéphane Auvin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures.

Authors:  Carol M Ulloa; Allen Towfigh; Joseph Safdieh
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.